source
- AstraZeneca's breast cancer pill camizestrant fails to improve progression-free survival in pivotal SERENA-4 trialAstraZeneca announced that its oral estrogen receptor degrader camizestrant, marketed as Etcamah, did not meet its primary endpoint in the phase III SERENA-4 trial. The study evaluated camizestran…
- Novartis encounters setbacks while AI firm Anthropic searches for a dealmakerThe latest Endpoints Weekly edition highlights a difficult period for Novartis, noting that the company is facing a series of setbacks. Details of the challenges are not provided, but the report s…